XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
License Agreements (Details)
€ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Jun. 30, 2020
EUR (€)
Nov. 01, 2019
USD ($)
Related Party Transaction [Line Items]              
Research and development $ 47,296,000 $ 31,774,000 $ 89,337,000 $ 55,177,000      
Accrued and other current liabilities 31,838,000   31,838,000   $ 23,829,000 [1]    
Equity method investment 4,677,000   4,677,000   4,892,000 [1]    
Research and development              
Related Party Transaction [Line Items]              
Collaboration arrangement, expense 400,000   700,000        
Notch Therapeutics, Inc.              
Related Party Transaction [Line Items]              
Equity method investment $ 4,700,000   $ 4,700,000   4,900,000   $ 5,000,000.0
Ownership percentage 25.00%   25.00%     25.00% 25.00%
Pfizer              
Related Party Transaction [Line Items]              
Royalty obligation period from date of first sale     12 years        
Pfizer | Asset Contribution Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments     $ 325,000,000.0        
Aggregate potential milestone payments $ 0 0          
Pfizer | Asset Contribution Agreement | Minimum              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments 30,000,000.0            
Pfizer | Asset Contribution Agreement | Maximum              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments 60,000,000.0            
Aggregate potential regulatory and development milestones 840,000,000.0            
Cellectis | Research Collaboration and License Agreement              
Related Party Transaction [Line Items]              
Maximum payments required per product against selected target     185,000,000.0        
Cellectis | Research Services | Research Collaboration and License Agreement              
Related Party Transaction [Line Items]              
Research and development 0 0 0 0      
Cellectis | Pre-Clinical Development Milestone | Research Collaboration and License Agreement              
Related Party Transaction [Line Items]              
Research and development 0 $ 0 0 $ 0      
Cellectis | Development and Sales | Maximum | Research Collaboration and License Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments     2,800,000,000        
Servier | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Research and development 2,400,000   $ 3,100,000        
Percentage of development costs payable by the Company     60.00%        
Percentage of development cost payable by collaboration partner     40.00%        
Recovery of research and development expense 900,000   $ 1,900,000        
Receivables 800,000   800,000        
Accrued and other current liabilities         2,200,000    
Servier | Regulatory Milestone | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone receivable 42,000,000.0   42,000,000.0        
Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments     137,500,000        
Servier | Sales Milestone | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone receivable 79,100,000   79,100,000     € 70.5  
Servier | Sales Milestone | Maximum | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments     78,000,000.0        
Notch Therapeutics, Inc. | Research Collaboration and License Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone payable $ 7,250,000   7,250,000        
Notch Therapeutics, Inc. | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Research and development         $ 10,000,000    
Collaboration agreement, upfront payment             $ 10,000,000.0
Notch Therapeutics, Inc. | Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments     4,000,000.0        
Notch Therapeutics, Inc. | Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement              
Related Party Transaction [Line Items]              
Aggregate potential milestone payments     $ 283,000,000.0        
[1] The balance sheet as of December 31, 2019 is derived from the audited financial statements as of that date.